Fig. 1
From: Generation and purification of iPSC-derived cardiomyocytes for clinical applications
Schematic overview of the workflow to produce purified transgene- and xenofree human iPSC-derived cardiomyocytes (iCMs). First somatic cells from a patient are reprogrammed into induced pluripotent stem cells (iPSCs). These iPSCs are differentiated into cardiomyocytes, followed by purification. Human iCMs are either replated or frozen for further applications, such as tissue engineering or disease modelling